CareDx (NASDAQ: CDNA) shares preliminary 2025 financial results update

Rhea-AI Filing Summary

CareDx, Inc. filed a current report to furnish a press release announcing its preliminary unaudited financial results for the quarter and year ended December 31, 2025. The press release, dated January 12, 2026, is included as Exhibit 99.1 to the report and is incorporated by reference.

The company states that this information is being furnished under the rules for current reports and is not deemed “filed” for purposes of certain liability provisions of the Exchange Act, nor automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.

0001217234FALSE00012172342026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 12, 2026

CAREDX, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

001-36536

94-3316839

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

8000 Marina Boulevard, 4th Floor

Brisbane, California 94005

(Address of Principal Executive Offices) (Zip Code)

(415) 287-2300

Registrant’s telephone number, including area code

N/A

(Former Name, or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

 Securities registered pursuant to Section 12(b) of the Exchange Act:

(Title of each class)

(Trading Symbol)

(Name of exchange on which registered)

Common Stock, $0.001 Par Value

CDNA

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 12, 2026, CareDx, Inc. (the “Company”) issued a press release announcing its preliminary unaudited financial results for the quarter and year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is intended to be furnished under Item 2.02 and Item 9.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
99.1						Press Release issued by CareDx, Inc., dated January 12, 2026.
104						Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 12, 2026			CAREDX, INC.
			By:			/s/ JOHN W. HANNA
						John W. Hanna
						Chief Executive Officer
						(Principal Executive Officer)

FAQ

What did CareDx (CDNA) disclose in this 8-K filing?

CareDx, Inc. furnished a press release announcing its preliminary unaudited financial results for the quarter and year ended December 31, 2025, as Exhibit 99.1.

Which period do the preliminary CareDx (CDNA) results cover?

The preliminary unaudited results cover both the quarter and full year ended December 31, 2025.

When did CareDx (CDNA) issue the preliminary results press release?

CareDx, Inc. issued the press release on January 12, 2026, and attached it to the report as Exhibit 99.1.

Are the CareDx (CDNA) preliminary results considered “filed” with the SEC?

The company states that the information in this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act.

What exhibits are included with this CareDx (CDNA) 8-K?

The report includes Exhibit 99.1, the press release announcing preliminary unaudited results, and Exhibit 104, the cover page interactive data file in iXBRL format.

Who signed the CareDx (CDNA) current report?

The report was signed on behalf of CareDx, Inc. by John W. Hanna, Chief Executive Officer and principal executive officer.